UCB (Belgium) has a monoclonal antibody candidate (romozumab) which has met its primary endpoints for a phase III Osteoporosis trial, FRAME in partnership with Amgen. The drug showed 75% improvement (compared to placebo) and few side effects.
UCB in Brussels is developing immunotherapies for a range of chronic diseases, which has now gotten good phase III results for an Osteoporosis drug. This is developed in partnership with Amgen (US), which already has the first ever FDA approved antibody drug for osteoporosis (denosumab).
Osteoporosis is a common disease, with higher incidence in post-menopausal women. Characterised by low bone mineral density (BMD), there is an increased the risk of skeletal fractures – which can be really serious.
Its effect in increasing BMD was evaluated in a previous phase II trial,